Cerillo’s Post

If you are planning to make it out to San Francisco next week for the JPM Biotech Showcase 2024, please do send me a note to my email at eric.brewster@pharpoint.com and we would be happy to schedule a time to meet with you and tell you more about PharPoints industry leading timelines (Database ready for sponsor - 15 days after final protocol received) and how we have been able to enroll recent studies well AHEAD of schedule! We look forward to seeing everyone there! #clinicalresearch #clinicaltrials #clinical #pharma #pharmaceutical #biostatistics #biotech #biotechnology #datamanagement

SequenTalks Episode 4 is out now! CJ and Andy discuss the use of Agiloft within the BioTech and Life Science industry. Check it out and let us know what you think, thank you!

Ribosome profiling provides insights into the real-time translation of proteins, a core process in understanding aging and disease. 🔬🧬 Known for their groundbreaking work in cellular rejuvenation, Altos Labs recently collaborated with Seqera and others to develop a new best-in-class Ribo-seq pipeline (nf-core/riboseq). 🚀 The new pipeline is based on nf-core best practices and will benefit the entire research community. 🌍👏 We applaud Altos Labs for their leadership and generosity in making Ribo-seq available to all! 🙌 To learn about the pipeline and how it was created, check out the joint article describing challenges faced, new pipeline features, and future opportunities for community collaboration. 👇 https://lnkd.in/ddemy_Yi

Driving meaningful innovative change across research & development to ensure a better understanding and predictability of safety events! A long term dream of mine. Enabling Translational Safety through collaboration. Co-Leading sustainability efforts across the ecosystem to enable high quatity product lifecycle management, efficiency and acceleration of medicines developmets.

Yesterday, I shared details of the successful biopesticide companies / products selected to join Platform10's first field trial cohort. It was a highly competitive selection process. You can view the original story here: https://lnkd.in/grf7kH2v

In 2016 the Stämm saga began! Fast forward to 2018, we’re a squad of 7 Stämmers. IndieBio, the powerhouse of biotech accelerators, hits us up – Yuyo Llamazares Vegh and Federico D'Alvia Vegh get the call. By 2019, we're 17 strong, cutting the ribbon on our very own lab in Buenos Aires. Looking back to those times we could never forsee the place we are at now. In 2020, with 25 Stämmers on board, we realized we were short in space, it was time to expand. Lab, offices, and workshops, we created the ideal space for our stämmers to put their disruptive ideas to the test. We entered 2021 with 70 Stämmers – that's almost triple! Hard-working people attract like-minded teammates. Research and development blooms under interdisciplinary teams. In 2022 we've hit 170 Stämmers! Multiplying faster than we can count, a solid teamwork framework helped us grow without losing our focus. And now, in 2023, we're wrapping it up with 216 unique Stämmers, each of them bringing singular talents to the table. Talk about spectacular growth! #StämmGrowth #ExponentialGrowth #TeamGoals #biotechnology

Why do Biotech companies use DON Monte Carlo? Biotech companies choose to use us for several reasons. DON Monte Carlo provides a platform for networking and connecting with key decision-makers in the industry. It offers opportunities to showcase their innovations, products, and services to a targeted audience of investors, potential partners, and industry experts. Additionally, DON Monte Carlo can help biotech companies gain visibility and access to funding opportunities, which are crucial for their research and development efforts. By participating in DON Monte Carlo, biotech companies can enhance their brand recognition, forge strategic partnerships, and accelerate their growth in the industry. Submit your opportunity here - https://lnkd.in/dcvSMynH Become a DON in 2024.

🌟 Exciting Reflections from COG Nordics 2024! 🌟 Last week, I had the pleasure of chairing a C-Suite panel at the COG Nordics conference in #Copenhagen, diving deep into the intricacies of funding for Nordic clinical-stage #biotechs. Joined by industry #leaders from MyCural Therapeutics, Alder Therapeutics, Amplio Pharma, and Node Pharma, we explored essential strategies to navigate the complex landscape of investment funding for clinical trials. Key Takeaways: - Early-Stage Funding: The critical role of securing initial resources can significantly impact the success and progress of clinical trials. - Expert Guidance: Leveraging expert advice is vital for bridging the communication gap between scientists and investors. - Networking: The importance of building robust connections within industry events to foster potential investment and collaboration opportunities. - Track Record: Establishing a credible and successful history to attract and reassure investors. Missed out on this insightful discussion? Don’t worry! Join us for our next meeting in Amsterdam this November for more enriching experiences. 🌍 Read Here: https://lnkd.in/efwYKWtT 📈 #Biotech #ClinicalTrials #InvestmentFunding #NordicBiotech #COGNordics2024 #HealthcareInnovation #ProfessionalNetworking

Want to hear from CSuite executives in biotech and life science about the latest cures? Join us at Vallavanda on Tuesday. Free to attend for CSuite execs and biotech leaders. Register at www.biomedley.org #csuite #biomedley

BioInnovate Ireland, the specialist medical device and health technology innovation programme at University of Galway, has launched its latest search for future healthcare innovators. The programme, which is formally affiliated to Stanford BioDesign and co-funded by the University and Enterprise Ireland, is hosting a special online event for anyone interested on Thursday February 8th from 7pm-8pm. Anyone interested can register on Eventbrite by following a link to the webinar on www.bioinnovate.ie Dr Sinead Walsh, Director of Operations at BioInnovate Ireland, explained the purpose of the event: “BioInnovate Ireland is committed to cultivating the next generation of healthcare leaders and entrepreneurs. Each year we welcome applications to the programme from diverse backgrounds, including clinical - all healthcare professionals; technical - engineers, scientists, data analysts, designers; commercial - business, MBA graduates, marketing leaders; and other highly motivated individuals interested in healthcare innovation. “The information evening is the perfect opportunity to explore the programme, hear from distinguished alumni and current fellows, and find out about the transformative impact the programme has had. To date, we have trained 148 Fellows and their work with us has led to 33 new start-up companies that have created new technologies which have benefitted more than 4,000 patients and raised more than €250million in private and public funding.” Professor Martin O’Halloran, the Executive Director of BioInnovate Ireland, outlined the programme structure: “The BioInnovate programme is affiliated with Stanford BioDesign and has three key stages - identify, invent and implement. It guides multidisciplinary teams through a full cycle of innovation, from identifying need, to designing and prototyping viable solutions, as well as securing funding.” BioInnovate Alumna Camille O'Malley is Co-Founder and Chief Technical Officer of XTremedy Medical, said: “The BioInnovate programme is a unique opportunity to explore the medtech entrepreneurship space. It offers candidates the chance to break into new career spaces and grow an expert network with the local and global medtech space. Alumni to date have gone on to found some of Ireland’s highest potential start-ups, develop breakthrough innovations for patients, lead venture capital teams and beyond.” The BioInnovate fellowship is a fully funded 10-month programme supported by Enterprise Ireland. It offers fellows with a tax-free monthly stipend of €3,800 and covers programme fees. BioInnovate Ireland is supported under the Innovators’ Initiative Programme co-funded by the Government of Ireland and the @European Union through the Northern and Western Regional Assembly Programme 2021-2027.